hereditary cancer
Case Study Suggests Use of Targeted Therapy, Surveillance for Germline ALK-Mutant Neuroblastoma
Premium
Two family members with a germline ALK-mutant neuroblastoma both experienced complete response to ALK inhibitors in a case study.
Nouscom to Advance Cancer Vaccine for Lynch Syndrome Into Registrational Study
The firm says it has a path forward for a Phase II/III registration-enabling study of NOUS-209 after positive meetings with the FDA.
Their study showed that DCIS patients with pathogenic variants in BRCA1/2 and PALB2 had a higher risk of developing invasive breast cancer than those without.
Risk-Reducing Surgery Improves Outcomes for Young Patients With BRCA1/2-Mutant Breast Cancer
Premium
A global study showed breast cancer patients who underwent preventive surgeries had lower mortality and cancer recurrence risks than those who didn't.
BRCA1/2 Mutations Aren't Equal: Researchers Push for Reduced Penetrance Pathogenic Variant Category
Premium
Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater recognition of such variants.